NPS nabs global Gattex rights in $80M buyback from Takeda

NPS Pharmaceuticals thinks going solo on Gattex marketing can deliver bigger bucks for its top line. The company struck an $80 million deal to buy back ex-U.S. rights to the short-bowel syndrome drug from Takeda. Report